Eli Lilly Verzenio usage split roughly three-ways in HR+ breast cancer, exec says

14 Dec 2018

Eli Lilly’s (NYSE:LLY) Verzenio (abemaciclib) usage within its three labelled indications in hormone receptor-positive (HR+) breast cancer has been approximately 20% as a late-line monotherapy, 30% as an initial therapy in combination with anastrozole, and 40% in combination with AstraZeneca’s (LON:AZN) Faslodex (fulvestrant), said Alex Horn, global development leader for Abemaciclib, Eli Lilly, Indianapolis.

The distribution is close to one third in each setting, Horn added. Verzenio’s sales were USD 21m in 4Q17 and 171.9m in the first three quarters of 2018. Analysts expect sales projections to hit USD 2.17bn in 2024.

Verzenio’s initial September 2017 approval was for its use in combination with Faslodex in HR+ HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy, and as a monotherapy following endocrine therapy and prior chemotherapy in the metastatic setting. It was later approved as an initial therapy in combination with endocrine therapy in February 2018.

After its 2017 approval, Verzenio saw initial uptake as a monotherapy or a second-line therapy in combination with Faslodex, but it has since seen growing use as an initial therapy after its February 2018 label expansion, as well as increased use among oncologists who have gained experience using it in later lines, said Horn.

Already a subscriber? Login to read the full article.

 
1 Start 2 Complete